结直肠癌
医学
微卫星不稳定性
CD8型
免疫疗法
免疫系统
转录组
癌症研究
内科学
细胞毒性T细胞
癌症
T细胞
肿瘤科
肿瘤浸润淋巴细胞
腺癌
生物
免疫学
基因
基因表达
体外
等位基因
微卫星
生物化学
作者
Momeneh Foroutan,Ramyar Molania,Aline Pfefferle,Corina Behrenbruch,Sebastian Scheer,Axel Kallies,Terence P. Speed,Joseph Cursons,Nicholas D. Huntington
标识
DOI:10.1158/2326-6066.cir-21-0137
摘要
Immunotherapy success in colorectal cancer is mainly limited to patients whose tumors exhibit high microsatellite instability (MSI). However, there is variability in treatment outcomes within this group, which is in part driven by the frequency and characteristics of tumor-infiltrating immune cells. Indeed, the presence of specific infiltrating immune-cell subsets has been shown to correlate with immunotherapy response and is in many cases prognostic of treatment outcome. Tumor-infiltrating lymphocytes (TIL) can undergo distinct differentiation programs, acquiring features of tissue-residency or exhaustion, a process during which T cells upregulate inhibitory receptors, such as PD-1, and lose functionality. Although residency and exhaustion programs of CD8+ T cells are relatively well studied, these programs have only recently been appreciated in CD4+ T cells and remain largely unknown in tumor-infiltrating natural killer (NK) cells. In this study, we used single-cell RNA sequencing (RNA-seq) data to identify signatures of residency and exhaustion in colorectal cancer-infiltrating lymphocytes, including CD8+, CD4+, and NK cells. We then tested these signatures in independent single-cell data from tumor and normal tissue-infiltrating immune cells. Furthermore, we used versions of these signatures designed for bulk RNA-seq data to explore tumor-intrinsic mutations associated with residency and exhaustion from TCGA data. Finally, using two independent transcriptomic datasets from patients with colon adenocarcinoma, we showed that combinations of these signatures, in particular combinations of NK-cell activity signatures, together with tumor-associated signatures, such as TGFβ signaling, were associated with distinct survival outcomes in patients with colon adenocarcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI